Join to View Full Profile
675 N Saint Clair StSte 21-100Chicago, IL 60611
Phone+1 312-695-0990
Fax+1 312-695-1106
Dr. Sosman is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
University of Wisconsin Hospitals and ClinicsFellowship, Medical Oncology, 1986 - 1989- University of Wisconsin Hospitals and ClinicsResidency, Internal Medicine, 1985 - 1986
University of ChicagoResidency, Pathology-Anatomic and Clinical, 1982 - 1985- University of ChicagoInternship, Internal Medicine, 1981 - 1982
Albert Einstein College of MedicineClass of 1981
Certifications & Licensure
IL State Medical License 1983 - 2026
TN State Medical License 2001 - 2016
WI State Medical License 1985 - 1989
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Medical Oncology
American Board of Pathology Anatomic Pathology
Clinical Trials
Publications & Presentations
PubMed
- 2 citationsPooled Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone in Patients With Advanced Melanoma.Georgina V Long, James Larkin, Dirk Schadendorf, Jean-Jacques Grob, Christopher D Lao
Journal of Clinical Oncology. 2025-03-10 - Presence of tertiary lymphoid structures and exhausted tissue-resident T cells determines clinical response to PD-1 blockade in renal cell carcinoma.Miya B Hugaboom, Lena V Wirth, Kelly Street, Neil Ruthen, Opeyemi A Jegede
Cancer Discovery. 2025-02-24 - 1 citationsWeight and Blood-Based Markers of Cachexia Predict Disability, Hospitalization and Worse Survival in Cancer Immunotherapy Patients.Steven D Tran, Noah J Forrest, Vijeeth Guggilla, Geovanni M Perottino, Jodi L Johnson
Journal of Cachexia, Sarcopenia and Muscle. 2025-02-01
Press Mentions
Reversing Resistance to PD-1 Inhibitors with Combination Immunotherapy in Patients with Advanced MelanomaApril 8th, 2022- ECOG-ACRIN Cancer Research Group Melanoma Research Team Led by Michael Atkins, MD, Receives the 2023 Paper of the Year Distinction from the Journal of Clinical OncologyJanuary 19th, 2024
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
